<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471744</url>
  </required_header>
  <id_info>
    <org_study_id>2005-004468-22</org_study_id>
    <secondary_id>ISRCTN 97864911</secondary_id>
    <nct_id>NCT00471744</nct_id>
  </id_info>
  <brief_title>HEAD-Study Optimizing the Treatment of Children With BECTS</brief_title>
  <acronym>HEAD</acronym>
  <official_title>HEAD-TO-HEAD Evaluation of the Antiepileptic Drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German Multi-Centre, Doubleblind Controlled Trial in Children With Benign Epilepsy With Centro-Temporal Spikes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that Levetiracetam is as effective as Sulthiame in the
      treatment of children with BECTS. Patients entering the HEAD-Studie are either treated with
      Leveitracetam or Sulthiame over a 6 months period. Patients are equally randomised to one of
      the two treatment regimens. Administration of medication as blinded capsules.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low patient number after 2 years recruiting
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of levetiracetam in the treatment of children with BECTS compared to sulthiame</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive effects</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy on EEG pattern</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">44</enrollment>
  <condition>Epilepsy, Rolandic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment with levetiracetam or sulthiame over a six-month period.</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 6 and 12 years

          2. Weight between 15 kg and 60 kg

          3. At least two preceding seizures within the last six months before study start

          4. Typical electroencephalogram (EEG) with Rolando focus (centrotemporal spike or
             sharp-wave-focus)

          5. Diagnosis of BECTS

          6. Written informed consent from parents and child

        Exclusion Criteria:

          1. Other forms of epilepsy (e.g. continuous spikes and waves during slow sleep [CSWS],
             Landau-Kleffner-syndrome)

          2. Preceding treatment with antiepileptic drugs

          3. Mental Retardation (intelligence quotient [IQ] &lt;85)

          4. Focal neurological deficit

          5. Relevant major internistic disease (e.g. hepatopathy, nephropathy, endocrinopathy)

          6. Participation in another clinical trial within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F Heinen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwigs-Maximilians-Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. von Haunersches Kinderspital</name>
      <address>
        <city>München</city>
        <zip>81371</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2007</study_first_submitted>
  <study_first_submitted_qc>May 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <last_update_submitted>January 28, 2009</last_update_submitted>
  <last_update_submitted_qc>January 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2009</last_update_posted>
  <keyword>benign epilepsy</keyword>
  <keyword>pediatrics</keyword>
  <keyword>children</keyword>
  <keyword>rolandic epilepsy</keyword>
  <keyword>levetiracetam</keyword>
  <keyword>sulthiame</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Rolandic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Sulthiame</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

